EYENOVIA, INC.
Condensed Balance Sheets
| June 30, | December 31, |
| 2020 | 2019 |
| (unaudited) |
| Assets |
| Current Assets: |
| Cash | $ | 10,186,171 | $ | 14,152,601 |
| Prepaid expenses and other current assets | 809,083 | 196,680 |
| Total Current Assets | 10,995,254 | 14,349,281 |
| Property and equipment, net | 313,438 | 230,538 |
| Security deposit | 119,035 | 117,800 |
| Total Assets | $ | 11,427,727 | $ | 14,697,619 |
| Liabilities and Stockholders' Equity |
| Current Liabilities: |
| Accounts payable | $ | 1,078,700 | $ | 1,541,358 |
| Accrued compensation | 573,906 | 916,873 |
| Accrued expenses and other current liabilities | 681,225 | 453,430 |
| Notes payable - current portion | 421,599 | - |
| Total Current Liabilities | 2,755,430 | 2,911,661 |
| Deferred rent | 45,345 | 45,351 |
| Notes payable - non-current portion | 307,646 | - |
| Total Liabilities | 3,108,421 | 2,957,012 |
| Commitments and contingencies (Note 7) |
| Stockholders' Equity: |
| Preferred stock, $0.0001 par value, 6,000,000 shares authorized; |
| 0 shares issued and outstanding as of June 30, 2020 and |
| as of December 31, 2019 | - | - |
| Common stock, $0.0001 par value, 90,000,000 shares authorized; |
| 19,943,683 and 17,100,726 shares issued and outstanding |
| as of June 30, 2020 and December 31, 2019, respectively | 1,994 | 1,710 |
| Additional paid-in capital | 76,454,839 | 69,409,949 |
| Accumulated deficit | (68,137,527 | ) | (57,671,052 | ) |
| Total Stockholders' Equity | 8,319,306 | 11,740,607 |
| Total Liabilities and Stockholders' Equity | $ | 11,427,727 | $ | 14,697,619 |

The accompanying notes are an integral part of these condensed financial statements.
2
| EYENOVIA, INC. |
| Condensed Statements of Operations |
| (unaudited) |

| For the Three Months Ended | For the Six Months Ended |
| June 30, | June 30, |
| 2020 | 2019 | 2020 | 2019 |
| Operating Expenses: |
| Research and development | $ | 2,915,250 | $ | 3,568,022 | $ | 6,549,537 | $ | 7,576,918 |
| General and administrative | 2,104,163 | 1,809,106 | 3,940,945 | 3,751,869 |
| Total Operating Expenses | 5,019,413 | 5,377,128 | 10,490,482 | 11,328,787 |
| Loss From Operations | (5,019,413 | ) | (5,377,128 | ) | (10,490,482 | ) | (11,328,787 | ) |
| Other Income: |
| Small Business Administration Economic |
| Injury Disaster grant | 10,000 | - | 10,000 | - |
| Interest expense | (6,351 | ) | - | (10,032 | ) | - |
| Interest income | 199 | 43,616 | 24,039 | 62,891 |
| Net Loss | $ | (5,015,565 | ) | $ | (5,333,512 | ) | $ | (10,466,475 | ) | $ | (11,265,896 | ) |
| Net Loss Per Share |
| - Basic and Diluted | $ | (0.25 | ) | $ | (0.44 | ) | $ | (0.56 | ) | $ | (0.94 | ) |
| Weighted Average Number of |
| Common Shares Outstanding |
| - Basic and Diluted | 19,821,215 | 12,034,450 | 18,563,864 | 11,975,035 |

The accompanying notes are an integral part of these condensed financial statements.
3
| EYENOVIA, INC. |
| Condensed Statements of Changes in Stockholders’ Equity |
| (unaudited) |
| For the Six Months Ended June 30, 2020 |
| Additional | Total |
| Common Stock | Paid-In | Accumulated | Stockholders' |
| Shares | Amount | Capital | Deficit | Equity |
| Balance - January 1, 2020 | 17,100,726 | $ | 1,710 | $ | 69,409,949 | $ | (57,671,052 | ) | $ | 11,740,607 |
| Issuance of common stock and warrants in public offering [1] | 2,675,293 | 267 | 5,451,475 | - | 5,451,742 |
| Stock-based compensation | - | - | 583,865 | - | 583,865 |
| Net loss | - | - | - | (5,450,910 | ) | (5,450,910 | ) |
| Balance - March 31, 2020 | 19,776,019 | 1,977 | 75,445,289 | (63,121,962 | ) | 12,325,304 |
| Exercise of stock warrants | 167,664 | 17 | 376,404 | - | 376,421 |
| Stock-based compensation | - | - | 633,146 | - | 633,146 |
| Net loss | - | - | - | (5,015,565 | ) | (5,015,565 | ) |
| Balance - June 30, 2020 | 19,943,683 | $ | 1,994 | $ | 76,454,839 | $ | (68,137,527 | ) | $ | 8,319,306 |

[1] Includes gross proceeds of $5,984,931, less total issuance costs of $533,189.
| For the Six Months Ended June 30, 2019 |
| Additional | Total |
| Common Stock | Paid-In | Accumulated | Stockholders' |
| Shares | Amount | Capital | Deficit | Equity |
| Balance - January 1, 2019 | 11,468,996 | $ | 1,147 | $ | 53,388,216 | $ | (36,514,294 | ) | $ | 16,875,069 |
| Exercise of stock options on a cashless basis | 236,466 | 24 | (24 | ) | - | - |
| Exercise of stock options | 313,686 | 31 | 483,857 | - | 483,888 |
| Stock-based compensation | - | - | 1,032,960 | - | 1,032,960 |
| Net loss | - | - | - | (5,932,384 | ) | (5,932,384 | ) |
| Balance - March 31, 2019 | 12,019,148 | 1,202 | 54,905,009 | (42,446,678 | ) | 12,459,533 |
| Exercise of stock options | 34,815 | 3 | 67,886 | - | 67,889 |
| Stock-based compensation | - | - | 424,019 | - | 424,019 |
| Net loss | - | - | - | (5,333,512 | ) | (5,333,512 | ) |
| Balance - June 30, 2019 | 12,053,963 | $ | 1,205 | $ | 55,396,914 | $ | (47,780,190 | ) | $ | 7,617,929 |

The accompanying notes are an integral part of these condensed financial statements.
4
| EYENOVIA, INC. |
| Condensed Statements of Cash Flows |
| (unaudited) |
| For the Six Months Ended |
| June 30, |
| 2020 | 2019 |
| Cash Flows From Operating Activities |
| Net loss | $ | (10,466,475 | ) | $ | (11,265,896 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |
| Depreciation and amortization | 49,343 | 5,106 |
| Stock-based compensation | 1,217,011 | 1,456,979 |
| Changes in operating assets and liabilities: |
| Prepaid expenses and other current assets | (137,187 | ) | (436,805 | ) |
| Accounts payable | (462,658 | ) | 216,186 |
| Accrued compensation | (342,967 | ) | (474,404 | ) |
| Accrued expenses and other current liabilities | 227,795 | (544,767 | ) |
| Security deposit | (1,235 | ) | - |
| Deferred rent | (6 | ) | 3,233 |
| Net Cash Used In Operating Activities | (9,916,379 | ) | (11,040,368 | ) |
| Cash Flows From Investing Activities |
| Purchases of property and equipment | (132,243 | ) | - |
| Net Cash Used In Investing Activities | (132,243 | ) | - |
| Cash Flows From Financing Activities |
| Proceeds from sale of common stock in private placement [1] | 5,569,136 | - |
| Proceeds from exercise of stock warrants | 376,421 | - |
| Proceeds from PPP 7(a) Loan | 463,353 | - |
| Repayments of notes payable | (209,324 | ) | - |
| Payment of private placement issuance costs | (117,394 | ) | - |
| Proceeds from exercise of stock options | - | 551,777 |
| Net Cash Provided By Financing Activities | 6,082,192 | 551,777 |
| Net Decrease in Cash and Cash Equivalents | (3,966,430 | ) | (10,488,591 | ) |
| Cash and cash equivalents - Beginning of Period | 14,152,601 | 19,728,200 |
| Cash and cash equivalents - End of Period | $ | 10,186,171 | $ | 9,239,609 |

[1] Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the offering proceeds.
| Supplemental Disclosure of Cash Flow Information: |
| Cash paid during the periods for: |
| Interest expense | $ | 6,032 | $ | - |
| Income taxes | $ | - | $ | - |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities |
| Purchase of insurance premium financed by note payable | $ | (475,216 | ) | $ | - |
| Exercise of stock options on a cashless basis | $ | - | $ | 24 |
| Deferred offering costs included in accounts payable | $ | - | $ | 77,376 |

The accompanying notes are an integral part of these condensed financial statements.
5
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1 – Business Organization, Nature of Operations and Basis of Presentation
Eyenovia. Inc. (“Eyenovia” or the “Company”) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system branded the Optejet®, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products.
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the operating results for the full year ending December 31, 2020 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2019 and for the year then ended, which were included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020.
Note 2 – Summary of Significant Accounting Policies
Since the date of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.
Liquidity and Going Concern
As of June 30, 2020, the Company had cash and cash equivalents of approximately $10.2 million and an accumulated deficit of approximately $68.1 million. For the six months ended June 30, 2020 and 2019, the Company incurred net losses of approximately $10.5 million and $11.3 million, respectively, and used cash in operations of approximately $9.9 million and $11.0 million, respectively. Subsequent to June 30, 2020, we entered into a License Agreement with Arctic Vision (Hong Kong) Limited (“Arctic Vision”) pursuant to which we received an upfront payment of $4.0 million before any payments to Senju Pharmaceutical Co., Ltd. (“Senju”). In addition, we received approximately $1.3 million from the exercise of warrants issued in our private placement of common stock and warrants that closed on March 24, 2020. See Note 11 – Subsequent Events for details.
The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.
The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.
6
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2 – Summary of Significant Accounting Policies – Continued
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.
The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of June 30, 2020 and December 31, 2019, the Company had cash balances in excess of FDIC insurance limits of $9,936,171 and $13,902,601, respectively.
Stock-Based Compensation
The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.
Convertible Instruments
The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.
If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.
Net Loss Per Common Share
Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.
The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:
| June 30, |
| 2020 | 2019 |
| Options | 3,290,357 | 1,563,366 |
| Warrants | 3,344,154 | - |
| Restricted stock units | 60,355 | 20,165 |
| Total potentially dilutive shares | 6,694,866 | 1,583,531 |

7
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2 – Summary of Significant Accounting Policies – Continued
Recently Adopted Accounting Pronouncements
In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.
Note 3 – Prepaid Expenses and Other Current Assets
As of June 30, 2020 and December 31, 2019, prepaid expenses and other current assets consisted of the following:
| June 30, | December 31, |
| 2020 | 2019 |
| (unaudited) |
| Prepaid insurance expenses | $ | 433,639 | $ | 33,923 |
| Payroll tax receivable | 176,385 | 95,233 |
| Prepaid Nasdaq annual fees | 65,420 | - |
| Prepaid research and development expenses | 26,660 | 17,978 |
| Prepaid patent expenses | 35,916 | 12,404 |
| Prepaid conference expenses | 35,003 | 10,600 |
| Prepaid rent and security deposit | 21,994 | 2,463 |
| Other | 14,066 | 24,079 |
| Total prepaid expenses and other current assets | $ | 809,083 | $ | 196,680 |

Note 4 – Accrued Compensation
As of June 30, 2020 and December 31, 2019, accrued compensation consisted of the following:
| June 30, | December 31, |
| 2020 | 2019 |
| (unaudited) |
| Accrued bonus expenses | $ | 380,320 | $ | 897,839 |
| Accrued payroll expenses | 193,586 | 19,034 |
| Total accrued compensation | $ | 573,906 | $ | 916,873 |

8
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 5 – Accrued Expenses and Other Current Liabilities
As of June 30, 2020 and December 31, 2019, accrued expenses and other current liabilities consisted of the following:
| June 30, | December 31, |
| 2020 | 2019 |
| (unaudited) |
| Accrued legal expenses | $ | 409,074 | $ | - |
| Accrued research and development expenses | 201,794 | 208,175 |
| Accrued professional services | 44,368 | 97,396 |
| Credit card payable | 19,887 | 56,979 |
| Leasehold improvements | - | 42,500 |
| Accrued franchise tax | - | 40,995 |
| Accrued travel and entertainment expenses | 5,730 | 7,385 |
| Other | 372 | - |
| Total accrued expenses and other current liabilities | $ | 681,225 | $ | 453,430 |

Note 6 – Notes Payable
As of June 30, 2020 and December 31, 2019, notes payable consisted of the following:
| June 30, | December 31, |
| 2020 | 2019 |
| (unaudited) |
| Paycheck Protection Program loan | $ | 463,353 | $ | - |
| Directors and officers insurance policy loan | 265,892 | - |
| 729,245 | - |
| Less current maturities | (421,599 | ) | - |
| $ | 307,646 | $ | - |

On February 24, 2020, the Company issued a note payable (the “Note”) for the purchase of a directors and officers liability insurance policy. The Note is payable in 9 monthly payments of $53,750 for an aggregate principal amount of $475,216. The Note accrues interest at a rate of 4.29% per year and matures on November 24, 2020. During the six months ended June 30, 2020, the Company repaid principal on the Note of $209,324.
On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the “PPP Loan”). The PPP Loan matures on May 3, 2022, and bears interest at a fixed rate of 1.00% per annum.
9
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 6 – Notes Payable – Continued
Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for certain permissible purposes as set forth in the PPP Loan, including, but not limited to, payroll costs and mortgage interest, rent or utility costs (collectively, “Qualifying Expenses”) incurred during the 24 weeks subsequent to funding, and on the maintenance of employee and compensation levels following the funding of the PPP Loan. The Company intends to use the proceeds of its PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness of its PPP Loan in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments of principal and interest are deferred until six months after the Small Business Administration makes a determination on forgiveness. While the PPP Loan currently has a two-year maturity, the amended law permits the borrower to request a five-year maturity from its lender.
During the three months ended June 30, 2020 and 2019, the Company recorded interest expense of $4,333 and $0, respectively, and $6,032 and $0 for the six months ended June 30, 2020 and 2019, respectively.
Note 7 – Commitments and Contingencies
Litigations, Claims and Assessments
The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.
Note 8 – Related Party Transactions
Consulting Agreements
A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $28,701 and $50,634 for the three months ended June 30, 2020 and 2019, respectively, and $57,402 and $98,835 for the six months ended June 30, 2020 and 2019, respectively, related to the agreement which was included within general and administrative expenses on the condensed statements of operations.
Lease Agreements
The Company’s Vice President of Research and Development and Manufacturing (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The lease agreement was amended again on April 6, 2020 to lease additional space and increase the monthly base rent and security deposit to $5,247. The Company made $70,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense amounted to $15,494 and $12,036 for the three months ended June 30, 2020 and 2019, respectively, and $27,530 and $24,072, respectively, for the six months ended June 30, 2020 and 2019, respectively.
10
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 8 – Related Party Transactions - Continued
Research and Development Activities
The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and six months ended June 30, 2020, the Company recognized research and development expense of $229,034 and $472,805, respectively, related to services provided by such vendor. During the three and six months ended June 30, 2019, the Company recognized research and development expense of $210,420 and $530,560, respectively, related to services provided by such vendor. The Company had a liability of $95,087 and $89,052 to the vendor as of June 30, 2020 and December 31, 2019, respectively.
The Company recognized $46,050 and $97,387 of compensation expense related to the VP of R&D’s salary during the three and six months ended June 30, 2020, respectively. The Company recognized $46,050 and $94,100 of compensation expense during the three and six months ended June 30, 2019, respectively.
License Agreement
On March 8, 2015, the Company entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license, with rights of sublicense, for its medical device technology for the piezoelectric delivery of ophthalmic medications to develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute such products in Asia. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject to certain adjustments upon the loss of patent coverage. The Exclusive License Agreement will continue in full force and effect, on a country-by-country basis, until the later to occur of: (i) the tenth (10th) anniversary of the first commercial sale of such a product candidate in a country or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there had been no commercial sales of such a product in Asia, and, therefore, no royalties had been earned. Senju is owned by the family of a former member of the Company’s Board of Directors and, together, they beneficially own greater than 5% of the Company’s common stock.
On April 8, 2020, Eyenovia entered into an amendment (the “License Amendment”) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the “Licensed Products”) previously licensed to Senju in China (including the People’s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the “Territory”) if such a license is executed by the Company by April 8, 2021. The Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.
Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Unless a third-party license is executed by the Company prior to April 8, 2021 (in which case, subject to early termination the License Amendment shall remain in effect for the duration of such license), the License Amendment terminates on April 8, 2021, but may be terminated earlier by Senju upon the Company’s material breach of the License Amendment, subject to a 60-day cure period.
The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the “Letter Agreement”). See Note 11 – Subsequent Events for details.
11
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity
Equity Incentive Plan
On April 7, 2020, the Company’s Board of Directors approved the Company’s Amended and Restated 2018 Omnibus Stock Incentive Plan (the “Restated Plan”), which stockholders approved on June 30, 2020. The Restated Plan makes certain changes to the Company’s 2018 Omnibus Stock Incentive Plan, as amended (the “2018 Plan”). For example, the Restated Plan increases the number of shares of Company’s common stock reserved for issuance under the 2018 Plan to 2,950,000 shares. The Restated Plan requires that all equity awards issued under the Restated Plan vest at least twelve months from the applicable grant date, subject to accelerated vesting, and provides that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with respect to unvested portions of equity may accrue and be paid when, and if, the awards later vest and the shares are actually issued to the grantee. In addition, the Restated Plan sets an annual limit on the grant date fair value of awards to any non-employee director, together with any cash fees paid during the year, of $150,000, subject to certain exceptions for a non-executive chair of the Board. Finally, the Restated Plan makes several administrative changes to the 2018 Plan, including to clarify that awards made under the Restated Plan are intended to be exempt from or comply with Section 409(A) of the Internal Revenue Code of 1986, as amended.
Securities Purchase Agreement
On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company’s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (“Class A Warrant”), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (“Class B Warrant”) (collectively, the Class A Warrants and Class B Warrants, the “Warrants”). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.45 million of net proceeds in the offering after deducting placement agent fees and offering expenses of $0.53 million. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. These Warrants, taken together, had an intrinsic value of $1,012,815 as of June 30, 2020. The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share. These Warrants, taken together, had an intrinsic value of $659,930 at June 30, 2020.
In connection with the offering, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3, which was declared effective by the SEC on May 13, 2020.
Stock Options
On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $89,400, which the Company expects to recognize over the vesting period.
On May 28, 2020, the Company granted ten-year stock options to purchase 263,500 shares of common stock to its employees under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.89 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $587,100, which the Company expects to recognize over the vesting period.
12
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity – Continued
Stock Options - Continued
On June 3, 2020, the Company granted ten-year stock options to purchase 764,419 shares of common stock to its executive directors under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.72 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $1,603,600, which the Company expects to recognize over the vesting period.
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:
| For the Three Months Ended | For the Six Months Ended |
| June 30, | June 30, |
| 2020 | 2019 | 2020 | 2019 |
| Expected term (years) | 5.85 | n/a | 5.85 | 5.85 |
| Risk free interest rate | 0.34% - 0.38% | n/a | 0.34% - 1.32% | 2.53% |
| Expected volatility | 99% | n/a | 96% - 99% | 139% |
| Expected dividends | 0.00% | n/a | 0.00% | 0.00% |

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not have a trading history to support its historical volatility calculations. Accordingly, the Company used a blended volatility whereby it uses its historical volatility for the period from its IPO through the valuation date and uses the average of peer-group data of six comparable entities to supplement its own historical data for the preceding years in computing its expected volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
The weighted average estimated grant date fair value of the stock options granted for the three months ended June 30, 2020 was approximately $2.13 per share. There were no stock options granted during the three months ended June 30, 2019. The weighted average estimated grant date fair value of the stock options granted for the six months ended June 30, 2020 and 2019 was approximately $2.17 and $2.50 per share, respectively.
A summary of the option activity during the six months ended June 30, 2020 is presented below:
| Weighted |
| Weighted | Average |
| Average | Remaining | Aggregate |
| Number of | Exercise | Life | Intrinsic |
| Options | Price | In Years | Value |
| Outstanding January 1, 2020 | 2,237,438 | $ | 3.51 |
| Granted | 1,052,919 | 2.81 |
| Exercised | - | - |
| Outstanding June 30, 2020 | 3,290,357 | $ | 3.29 | 8.3 | $ | 1,131,580 |
| Exercisable June 30, 2020 | 1,436,735 | $ | 3.38 | 6.9 | $ | 1,019,817 |

13
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity - Continued
Stock Options – Continued
The following table presents information related to stock options as of June 30, 2020:
| Options Outstanding | Options Exercisable |
| Weighted |
| Outstanding | Average | Exercisable |
| Exercise | Number of | Remaining Life | Number of |
| Price | Options | In Years | Options |
| $ | 1.24 | 260,000 | 4.7 | 260,000 |
| $ | 1.95 | 700,281 | 7.0 | 678,127 |
| $ | 2.72 | 764,419 | - | - |
| $ | 2.74 | 6,000 | 8.5 | 2,833 |
| $ | 2.89 | 263,500 | - | - |
| $ | 3.11 | 681,572 | 9.1 | 45,285 |
| $ | 4.00 | 2,000 | 8.4 | 1,056 |
| $ | 4.68 | 25,000 | - | - |
| $ | 5.10 | 6,000 | 8.2 | 3,500 |
| $ | 5.19 | 16,500 | 8.2 | 9,625 |
| $ | 5.25 | 26,668 | 6.3 | 24,582 |
| $ | 6.20 | 311,499 | 8.1 | 251,933 |
| $ | 6.30 | 60,000 | 8.0 | 38,333 |
| $ | 8.72 | 166,918 | 7.8 | 121,461 |
| 3,290,357 | 6.9 | 1,436,735 |

Stock-Based Compensation Expense
The Company recorded stock-based compensation expense related to stock options and restricted stock units. During the three months ended June 30, 2020 and 2019, the Company recorded expense of $633,146 ($348,447 of which was included within research and development expenses and $284,699 was included within general and administrative expenses on the condensed statement of operations) and $424,019 ($206,834 of which was included within research and development expenses and $217,185 was included within general and administrative expenses on the condensed statements of operations), respectively. During the six months ended June 30, 2020 and 2019, the Company recorded expense of $1,217,011 ($655,856 of which was included within research and development expenses and $561,155 was included within general and administrative expenses on the condensed statements of operations) and $1,456,979 ($900,917 of which was included within research and development expenses and $556,062 was included within general and administrative expenses on the condensed statements of operations) during the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, there was $4,312,311 of unrecognized stock-based compensation expense which the Company expects to recognize over a weighted average period of 2.3 years.
Warrant Exercises
During the three and six months ended June 30, 2020, Warrants to purchase 91,453 and 76,211 shares of common stock with an exercise price of $2.058 and $2.4696 per share, respectively, were exercised for aggregate proceeds of $376,421.
14
EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 10 – Employee Benefit Plans
401(k) Plan
In April 2019, the Company adopted the Eyenovia 401(k) Plan (the “Plan”), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2020, the Company’s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the six months ended June 30, 2020 and 2019, the Company recorded expense of $80,486 and $16,043 associated with its matching contributions, respectively. During the three months ended June 30, 2020 and 2019, the Company recorded expense of $22,515 and $0 associated with its matching contributions, respectively.
Note 11 – Subsequent Events
Warrant Exercises
Subsequent to June 30, 2020, Warrants to purchase 497,908 and 94,840 shares of common stock with an exercise price of $2.058 and $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $1.3 million.
License Agreements
On August 10, 2020, Eyenovia entered into a License Agreement (the “License Agreement”) with Arctic Vision pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
Under the terms of the License Agreement, Eyenovia received an upfront payment of $4.0 million before any payments to Senju. In addition, Eyenovia may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Arctic Vision also will purchase its supply of MicroPine and MicroLine from Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. Eyenovia will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Exclusive License Agreement with Senju, as amended by the License Amendment dated April 8, 2020, and a Letter Agreement dated August 10, 2020.
15
The following discussion and analysis of the results of operations and financial condition of Eyenovia, Inc. (“Eyenovia,” the “Company,” “we,” “us” and “our”) as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019 should be read in conjunction with our unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020.
Forward Looking Statements
This report contains “forward-looking statements.” Specifically, all statements other than statements of historical facts included in this report, including regarding our financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “continue” “intend,” and “plan” and words or phrases of similar import are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” included in our most recent Annual report on Form 10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Overview
We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than traditional eye drops (~ 90% vs. ~ 50%). Eyenovia’s technology also can deliver up to a 75% reduction in ocular drug and preservative exposure and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials. Using the Optejet, Eyenovia is developing the next generation of smart ophthalmic therapeutics which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration, or the FDA. Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products.
On October 29, 2019, the Company announced that it is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its MicroPine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs.
Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eye’s ability to focus on nearby objects. There currently are no known FDA-approved drugs for the improvement of near vision in patients with presbyopia, although other companies have related therapies in their pipeline. Eyenovia has planned two Phase III VISION trials for MicroLine. MicroPine is the Company’s first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the United States. In February 2019, the FDA accepted Eyenovia’s investigational new drug application, or IND, to initiate its Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. Eyenovia enrolled its first patient in the CHAPERONE study in June 2019. Due to the COVID-19 pandemic, the Company has previously experienced delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites. However, the Company has since been able to resume enrollment in the CHAPERONE study, and in the coming months, subject to any impacts of the COVID-19 pandemic, anticipates initiating its Phase III VISION trials for MicroLine. In addition, on August 10, 2020, the Company entered into License Agreement with Arctic Vision (Hong Kong) Limited (“Arctic Vision”) to develop and commercialize MicroPine for the treatment progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
MicroStat is Eyenovia’s fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. Eyenovia has completed its Phase III trials for MicroStat and announced positive results from these studies, known as MIST-1 and MIST-2. The Company currently remains on track to file a new drug application, or NDA, with the FDA for MicroStat in 2020, although the COVID-19 pandemic could change that.
16
Results from our previous three Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating our mydriatic agents demonstrated how the Optejet consistently delivered precision dosing at the volume of the eye’s natural tear film capacity of 6-8 µL, which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects. In the third study, we evaluated usability, patient tolerability and IOP lowering of microdosed latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in more than 90% of cases. Based on the results from these clinical trials, we are advancing MicroLine, MicroPine, MicroStat, and MicroProst (should we resume the program) utilizing the 505(b)(2) pathway. Where possible, we also intend to use this pathway for future clinical trials in new indications with significant unmet needs.
We have not completed development of any product candidate and we have therefore not generated any revenues from product sales.
Historically, we have financed our operations principally through equity offerings, including our initial public offering, numerous follow-on public offerings in 2018 and 2019, and our private placement that closed in March 2020. Based upon our current operating plan, there is substantial doubt about our ability to continue as a going concern for a period of at least the next twelve months. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support our future operations. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs.
Our net losses were $5.0 million and $10.5 million for the three and six months ended June 30, 2020. As of June 30, 2020, we had working capital and an accumulated deficit of $8.2 million and $68.1 million, respectively.
Financial Overview
Revenue
We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic product candidates.
Research and Development Expenses
Research and development expenses are incurred in connection with the research and development of our microdose-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:
| · | direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities; |

| · | personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and |

| · | facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities. |

We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.
We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.
17
General and Administrative Expenses
General and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to continue increasing.
Results of Operations
Three Months Ended June 30, 2020 Compared with Three Months Ended June 30, 2019
Research and Development Expenses
Research and development expenses for the three months ended June 30, 2020 totaled $2.9 million, a decrease of $0.7 million, or 18%, as compared to $3.6 million recorded for the three months ended, June 30, 2019. Research and development expenses consisted of the following:
| For the Three Months Ended |
| June 30, |
| 2020 | 2019 |
| Direct clinical and non-clinical expenses | $ | 1,503,565 | $ | 2,219,648 |
| Personnel-related expenses | 727,519 | 783,708 |
| Non-cash stock-based compensation expenses | 348,447 | 206,834 |
| Supplies and materials | 284,908 | 352,916 |
| Facilities and other expenses | 50,811 | 4,916 |
| Total research and development expenses | $ | 2,915,250 | $ | 3,568,022 |

The decrease in direct clinical and non-clinical expenses, personnel-related expenses and supplies and materials was primarily due to a decrease in activity related to the impact of the COVID–19 pandemic and the resulting social distancing and shelter in place orders. The increase in non-cash stock-based compensation expense was due to additional stock options that were granted subsequent to June 30, 2019. The increase in facilities and other expenses is due to an increase in depreciation on newly acquired assets in addition to an increase in travel-related expenses related to clinical studies.
General and Administrative Expenses
General and administrative expenses for the three months ended June 30, 2020 totaled $2.1 million, an increase of $0.3 million, or 16%, as compared to $1.8 million recorded for the three months ended June 30, 2019. This increase was primarily attributable to a $0.5 million increase in professional services related to business development activities. This was offset by a decrease of $0.1 million in advertising and marketing and $0.1 million in travel expenses related to the impact of the COVID-19 pandemic.
Six Months Ended June 30, 2020 Compared with Six Months Ended June 30, 2019
Research and Development Expenses
Research and development expenses for the six months ended June 30, 2020 totaled $6.5 million, a decrease of $1.0 million, or 14%, as compared to $7.6 million recorded for the six months ended, June 30, 2019. Research and development expenses consisted of the following:
18
| For the Six Months Ended |
| June 30, |
| 2020 | 2019 |
| Direct clinical and non-clinical expenses | $ | 3,330,782 | $ | 4,409,969 |
| Personnel-related expenses | 1,642,668 | 1,524,941 |
| Non-cash stock-based compensation expenses | 655,856 | 900,917 |
| Supplies and materials | 782,504 | 732,262 |
| Facilities and other expenses | 137,727 | 8,829 |
| Total research and development expenses | $ | 6,549,537 | $ | 7,576,918 |

The decrease in direct clinical and non-clinical expenses was primarily due to a decrease in activity related to the impact of the COVID–19 pandemic and the resulting social distancing and shelter in place orders. The increase in personnel-related expenses and supplies and materials and facilities and other expenses was primarily due to the hiring of two additional employees as we expanded our research and development activities for our microdose therapeutics in the second half of 2019. The decrease in non-cash stock-based compensation expense as compared to the 2019 period was primarily due to certain stock options that were accelerated and immediately vested in February 2019 slightly offset by additional options granted subsequent to June 30, 2019.
General and Administrative Expenses
General and administrative expenses for the six months ended June 30, 2020 totaled $3.9 million, an increase of $0.1 million, or 5%, as compared to $3.8 million recorded for the six months ended June 30, 2019. This increase was primarily attributable to a $0.4 million increase in professional services related to business development activities and $0.2 million in patent related expenses which is expected to continue to increase as programs are further developed. This was offset by a $0.3 million decrease in travel and entertainment expenses and $0.2 million in contracted services and marketing related to the impact of the COVID-19 pandemic.
Liquidity and Capital Resources
Since inception, we have experienced negative cash flows from operations. As of June 30, 2020, our accumulated deficit since inception was $68.1 million.
As of June 30, 2020, we had a cash balance of $10.2 million, working capital of $8.2 million and stockholders’ equity of $8.3 million. As of June 30, 2020 and December 31, 2019, we had $0.7 million and $0, respectively, of debt outstanding.
Subsequent to June 30, 2020, we entered into a License Agreement with Arctic Vision in which we received an upfront payment of $4.0 million before any payments to Senju. In addition, we received approximately $1.3 million from the exercise of warrants issued in our private placement that closed on March 24, 2020.
These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.
During the six months ended June 30, 2020 and 2019, our sources and uses of cash were as follows:
Net cash used in operating activities for the six months ended June 30, 2020 was $9.9 million, which includes cash used to fund a net loss of $10.5 million, reduced by $1.3 million of non-cash expenses, plus $0.7 million of cash used to fund changes in operating assets and liabilities. Net cash used in operating activities for the six months ended June 30, 2019 was $11.0 million, which includes cash used to fund a net loss of $11.3 million, reduced by $1.5 million of non-cash expenses, plus $1.2 million of cash used to fund changes in operating assets and liabilities.
Cash used in investing activities for the six months ended June 30, 2020 was $0.1 million, which was related to purchases of property and equipment. There was no cash used in investing activities for the six months ended June 30, 2019.
19
Net cash provided by financing activities for the six months ended June 30, 2020 totaled $6.1 million, which was attributable to aggregate net proceeds from the sale of common stock and warrants in our private placement of $5.4 million, $0.5 million in proceeds from a loan in connection with the Paycheck Protection Program under the Cares Act and $0.4 million of proceeds from the exercise of stock warrants. This was slightly offset by the repayment of notes payable of $0.2 million. Cash provided by financing activities for the six months ended June 30, 2019 totaled $0.6 million, which was attributable to proceeds from the exercise of stock options.
Off-Balance Sheet Arrangements
There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.
Critical Accounting Policies
For a description of our critical accounting policies, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.
Recently Adopted Accounting Pronouncements
For a description of recently adopted accounting pronouncements, including adoption dates and estimated effects, if any, on our condensed financial statements, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.
Smaller reporting companies such as us are not required to provide the information required by this item.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Based on their evaluation, our principal executive officer and principal financial and accounting officer concluded that as of June 30, 2020 our disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures as of June 30, 2020.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting that occurred during the second quarter of 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
20
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors.
Smaller reporting companies such as us are not required to provide the information required by this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
Item 3. Defaults upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
21
| Exhibit | Incorporated by Reference (Unless Otherwise Indicated) |
| Number | Exhibit Description | Form | File No. | Exhibit | Filing Date |
| 10.24* | Amendment to the Exclusive License Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated April 8, 2020 | — | — | — | Filed herewith |
| 10.25 | Promissory Note and Agreement dated May 3, 2020 | 8-K | 001-38365 | 10.24 | May 8, 2020 |
| 10.26# | Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan | 8-K | 001-38365 | 10.25 | July 2, 2020 |
| 10.27* | Letter Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated August 10, 2020 | — | — | — | Filed herewith |
| 10.28* | License Agreement by and between Eyenovia, Inc. and Artic Vision (Hong Kong) Limited, dated August 10, 2020 | — | — | — | Filed herewith |
| 31.1 | Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 31.2 | Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.1 | Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.2 | Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 101 | Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of June 30, 2020 and December 31, 2019; (ii) Condensed Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019; (iii) Condensed Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2020 and 2019; Condensed Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019; and (iv) Notes to Condensed Financial Statements |

* Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10).
# Management contract or other compensatory plan.
22
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| EYENOVIA, INC. |
| August 14, 2020 | By: | /s/ John Gandolfo |
| John Gandolfo |
| Chief Financial Officer (Principal Financial and Accounting Officer) |

23

Question: What is the percentage of the company's annual net loss that the stock-based compensation represents for the year ended June 30, 2019, to the nearest two decimal places?

Solution:
def solution():
    #Define variables name and value
    annual_stock_compensation = 1456979
    annual_net_loss = 11265896

    #Do math calculation to get the answer
    stock_compensation_percentage = (annual_stock_compensation / annual_net_loss) * 100
    answer = round(stock_compensation_percentage, 2)
    return answer


Answer: 12.93